Phase II evaluation of topotecan for pediatric central nervous system tumors

Cancer

Volumn 78, Issue 3, 1996, Pages 527-531

  Blaney, Susan M ^a,i   Phillips, Peter C ^b   Packer, Roger J ^c   Heideman, Richard L ^d   Berg, Stacey L ^a,i   Adamson, Peter C ^a   Allen, Jeffrey C ^e   Sallan, Stephen E ^f   Jakacki, Regina I ^g   Lange, Beverly J ^b   Reaman, Gregory H ^c   Horowitz, Marc E ^h   Poplack, David G ^h   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g RILEY HOSPITAL FOR CHILDREN   (United States)

^h TEXAS CHILDREN S HOSPITAL   (United States)

ⁱ TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

brain tumors; phase II trial; topoisomerase I; topotecan

Indexed keywords

TOPOTECAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BRAIN CANCER; BRAIN STEM TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEDULLOBLASTOMA; NEUROEPITHELIOMA; PRIORITY JOURNAL;

EID: 8944222113     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960801)78:3<527::aid-cncr21>3.0.co;2-#     Document Type: Article

References (17)

1. Hertzberg RK, Caranfa M, Hecht S. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989;28:4629-38.
2. Liu L. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989;58:351-75.
3. Blaney S, Cole D, Balis F, Godwin K, McCully C, Poplack D. Plasma and CSF pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1992;53:725-7.
4. Sung C, Blaney S, Cole D, Balis F, Dedrick R. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res 1994;54:5118-22.
5. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylamiomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994;34:171-4.
6. Blaney S, Balis F, Cole D, Craig C, Reid J, Ames M, et al. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993;43:1032-6.
7. Rowinsky E, Grochow L, Hendricks C, Ettinger D, Forastiere A, Hurowitz L, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-56.
8. Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzu-Jyun Y, et al. Phase I and clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993;85:1499-1507.
9. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, et al. Phase I and clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J Clin Oncol 1995;13:1768-76.
10. Smith M, Underleider R, Horowitz M, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-70.
11. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2(11):1281-8.
12. Carde P. MacKintosh F, Rosenberg S. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983;1:146-53.
13. National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treantment, National Cancer Institute, 1988.
14. Blaney S, Seibel N, O'Brien M, Mosher R, Reaman G, Poplack D, et al. A phase I study of taxotere in pediatric patients. [abstract No. 2327]. Proc Am Assoc Cancer Res 1993;34:211.
15. Houghton P, Cheshire P, Myers L, Stewart C, Synold T, Houghton J. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-39.
16. Castleberry R, Cantor A, Green A, Joshi V, Berkow R, Buchanan G, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 1994;12:1616-20.
17. Horowitz M, Etcubanas E, Christensen M, Houghton J, George S, Green A, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988;6:308-14.